NICE has recommended interim funding on England’s NHS for AstraZeneca’s ovarian cancer drug Lynparza in the earlier stages of the disease as a maintenance treatment after an initial round o
AstraZeneca has upped its revenue expectations following a strong second quarter, saying that sales of newer drugs will offset a major patent expiry and the impact of Brexit.
MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.
